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Background: There is a critical need for proven drugs other than non-steroidal anti-inflammatory drugs for
treatment of degenerative joint disease (DJD) pain in dogs. Antibodies against nerve growth factor (NGF) are
analgesic in rodent models and in humans with DJD. This pilot study aimed to evaluate the efficacy of a novel
caninised anti-NGF antibody (NV-01) for the treatment of DJD pain in dogs. In a randomized, parallel group,
stratified, double masked, placebo controlled, proof of principle clinical pilot study design, 26 dogs with DJD
received NV-01 (200 mcg/kg IV) or placebo on day 0 (D0). In addition to objective accelerometry measures, owners
completed clinical metrology instruments (Client-Specific Outcome Measures [CSOM], Canine Brief Pain Inventory
[CBPI] and Liverpool Osteoarthritis in Dogs Index [LOAD]) on D0, D14 and D28. CBPI subscales (pain severity [PS]
and pain interference [PI]), CSOM and LOAD scores were evaluated within and between groups for change over
time. Recognized success/failure criteria were applied and success compared between groups.
Results: CBPI PS and PI scores significantly improved in the NV-01 group (PS: D0-14, P = 0.012 and D0-28, P = 0.019;
PI: D0-14, P = 0.012 and D0-28, P = 0.032) but not in the placebo group. CSOM scores showed similar patterns with
a significant difference between within-group changes at D14 and D28 (P = 0.038 and P = 0.009, respectively), and
significantly more successes at D28 (P = 0.047). LOAD scores significantly improved in the NV-01 group (D0-14,
P = 0.004 and D0-28, P = 0.002) but not in the placebo group. There were significant differences between the
groups for change in LOAD score at D14 (P = 0.014) and D28 (P = 0.033). No side effects were noted. Activity in the
NV-01 group increased over the study period compared to placebo (P = 0.063) and the difference between the
groups for change in activity over the time period 9am-5pm (8 hours) was significant (P = 0.006).
Conclusions: These pilot data demonstrate a positive analgesic effect of anti-NGF antibody in dogs suffering from
chronic pain. The magnitude of the effect appeared identical to that expected with an NSAID.
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In veterinary medicine, the mainstay of drug therapy for
the alleviation of clinical signs associated with osteoarth-
ritis (OA) or degenerative joint disease (DJD)-associated
pain in dogs are the non-steroidal anti-inflammatory drugs
(NSAIDs). This may be partly due to the fact that there
are no other classes of drug approved by the Food and
Drug Administration – Center for Veterinary Medicine
(FDA-CVM) for the control of DJD-associated pain in
dogs. Despite some data to indicate efficacy of other drugs
for OA-associated pain in dogs [1], evidence-based data
indicates NSAIDs are currently considered the most ef-
fective therapy for DJD-associated pain [2-4]. However,
NSAIDs are not always sufficiently effective [1] and con-
cerns about side effects result in a large unmet need in the
treatment of canine DJD-associated pain.
Targeting nerve growth factor (NGF) has emerged as a
potentially useful therapeutic avenue for pain control.
NGF was originally identified as a critical factor for the
development and maintenance of sensory and sympathetic
neurons in the developing nervous system. However, it is
now clear that the dependence of these neurons on NGF
for survival is restricted to a brief time during develop-
ment and in the adult system, NGF has an important role
in pro-nociception via its effects on the NGF-specific tyro-
sine kinase receptor (TrkA) (reviewed in [5]).
NGF binds to the high-affinity NGF-specific TrkA which
results in autophosphorylation of the TrkA intracellular do-
main and activation of subsequent downstream signaling
cascades (reviewed in [5]). This results in post-translational
changes in the transient receptor potential vanilloid recep-
tor 1 (TRPV1) cation channel, increasing its excitability,
and further upregulation of other proteins that increase the
excitability of the primary afferent fiber [5]. NGF also acti-
vates mast cells, and thus further sensitizes neurons as a re-
sult of the products released by mast cells [6]. Given its role
in nociception, various ways of preventing activation of
TrkA have been explored, including removing free NGF,
preventing NGF binding to TrkA or preventing activation
of TrkA [7]. Of these approaches, neutralizing monoclonal
antibodies (mAb) targeting NGF (‘removing free NGF’)
have been developed first.
Inhibition of NGF function via anti-NGF antibodies
markedly reduces hyperalgesia and behavioral indicators
of pain in various animal models of inflammatory arth-
ritis [8,9]. In human clinical studies, several anti-NGF
mAbs have been evaluated and been shown to reduce
pain and improve function in patients with OA [10-14].
However, it is apparent that pain disorders display sig-
nificant differences in their responsiveness to anti-NGF
agents [15].
Recently, a canine-specific mAb against NGF (termed
NV-01) was described and reported to have high affinity
and potency, no effector activity, a long half-life and lowimmunogenic potential [16]. One recent report sug-
gested that this caninised anti-NGF mAb may provide
alleviation of the signs of pain in dogs with osteoarthritis
[17]. In that study, all dogs received the mAb with the
time of administration being randomized and blinded.
Although this innovative design provides initial informa-
tion on the efficacy of this NGF-neutralizing antibody,
the pervasive placebo effect known to occur in canine OA
trials [18] and the lack of objective measures used indicated
that a more comprehensive study design was desirable to
fully assess the potential utility of this therapeutic [17].
The aim of the present study was to further assess the
pain alleviating and function enhancing effects of NV-01
in dogs with DJD-associated pain and mobility impair-
ment. Our hypothesis was that a single treatment of
NV-01 would decrease pain and improve mobility in
dogs with DJD-associated pain for 4 weeks, as measured
by owner-completed clinical metrology instruments
(CMIs) and objectively measured activity. Specifically,
using a randomized, parallel group, stratified, double
masked, placebo controlled, proof of principle clinical
pilot study design we aimed to assess the pain-
alleviating and activity enhancing effects of NV-01 in
dogs with DJD-associated pain, using the primary out-
come measures of CMIs and actimetry data. In
addition, we aimed to evaluate the effects of NV-01 on
index joint pain, total joint pain score, owner-assessed
side effects, hematology, clinical chemistry and urinaly-
sis as secondary outcome measures.
Results
The study was conducted between May and December
2013. Eighty-one enquiries from interested dog owners
were received and following a telephone discussion, this
resulted in 37 screening appointments (Figure 1). Of
these, there were 11 screening failures: 4 for lack of
radiographic findings of DJD; 3 for insufficient degree of
impairment on the CSOM (Client-Specific Outcome
Measures); 2 because of significant stifle instability asso-
ciated with cruciate ligament rupture; 2 due to concur-
rent neurologic disease. Twenty-six dogs entered the
study. There were no differences between the groups with
respect to age, sex distribution, body weight or body con-
dition score (Table 1). There was even distribution of
index joints/regions across the two groups (Table 2).
Of the 26 dogs, 25 completed the 28-day study (Figure 1).
One dog was withdrawn just after the D14 assessment due
to cruciate ligament rupture. This occurrence was not con-
sidered to be treatment related.
Canine brief pain inventory pain severity score (CBPI PSS)
The treatment group improved significantly over time (at
D14, P = 0.012 and at D28, P = 0.019). The placebo group
did not improve significantly over time (at D14, P = 0.164
Figure 1 Study participant flow diagram.
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ences between the groups at any time point for abso-
lute scores, or change in scores. These scores and
changes are tabulated in Table 3. Using a comparison
of changes in CBPI PSS scores, the treatment effect size
was 0.56 at D14 and 0.46 at D28.Table 1 Enrolled dog demographic summary on D0 of study
(treatment day)
NV-01 Placebo P-value for comparison
of treatment groups














5 (5-8) 6 (5-7) 0.713 (Wilcoxon
Rank Sums)Canine brief pain inventory pain interference score (CBPI PIS)
The treatment group improved significantly over time (at
D14, P = 0.012 and at D28, P = 0.032). The placebo group
did not improve significantly over time (at D14, P = 0.06
and at D28, P = 0.11). There were no statistical differences
between the groups at any time point for absolute scores,
or change in scores. These scores and changes are tabu-
lated in Table 4. Using a comparison of changes in CBPI
PIS scores, the treatment effect size was 0.73 at D14 and
0.38 at D28.Canine brief pain inventory success/failure
At D14, there were more successes in the NV-01 group
(6/12, 50%) than the placebo group (1/12, 8.3%) (P =
0.069). Again, at D28 there was no difference between
groups in success/failure (P = 0.214) but there were more
successes in the NV-01 group (6/11, 55%) than the pla-
cebo group (3/12, 25%).
Table 2 Index joint or index axial skeleton region
distribution of the enrolled dogs on D0
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The NV-01 group improved significantly over time (at
D14, P = 0.004 and at D28, P = 0.001). The placebo
group improved significantly over time at D14, P =
0.031, but not at D28, P = 0.078. At D14 and D28, the
NV-01 group had lower scores (better ability to perform
the activities) than the placebo group (P = 0.011 and P =
0.032 respectively). Additionally, the degree of improve-
ment over D0 to D14, and D0 to D28 was significantly
greater in the NV-01 group than the placebo group (P =
0.038 and P = 0.009 respectively). These scores and
changes are tabulated in Table 5.
At D14 there were more successes in the NV-01 group
(9/13, 69%) versus the placebo group (6/13, 46%), but
this was not significant (P = 0.269). At D28, there was a
significant difference between groups in the number of
successes (P = 0.047) with 8/12 (67%) being classified as
successes in treatment group versus 3/13 (23%) in the
placebo group.
Liverpool osteoarthritis in dogs (LOAD)
The NV-01 group improved significantly over time (at
D14, P = 0.004 and at D28, P = 0.002) (Figure 2a). The
placebo group did not improve over time (at D14, P =
0.099, and at D28, P = 0.348) (Figure 2b). There were no
significant differences between the groups at D0, D14 or
D28 in total LOAD scores. However, the change in score
over D0 to D14, and D0 to D28 was significantly greater
in the NV-01 group than the placebo group (P = 0.014
and P = 0.033 respectively). These scores and changes
are tabulated in Table 6. Using a comparison of changes
in LOAD scores, the treatment effect size was 1.15 at
D14 and 0.96 at D28.Table 3 Summary of medians, range and statistical compariso
Scores (CBPI PSS) at D0, D14 and D28 of the study
Group D0 D14 D28 D
NV-01 4.75 (1.75-9.00) 2.00 (0.50-6.25) 2.63 (1.00 – 7.00) 1.
Placebo 3.75 (1.25-8.50) 3.00 (1.00-8.75) 3.00 (1.00 – 8.00) 0.
Between group
comparison P-value
0.898 0.719 0.744 0.
Decreases in scores signify improvement, and positive values for change indicate imActivity monitoring
The mean activity over 24 hours during the baseline period
(Days -7 to -1) is shown in Figure 3. Using the average ac-
tivity per minute over the baseline and final week (Days 20-
27), activity in the NV-01 group increased over the duration
of the study (significant on 1-sided t-test, P = 0.045; signifi-
cant at the 10% level on 2-sided t-test, P = 0.090). Activity
in dogs in the placebo group did not change over the
duration of the study (1-sided t-test, P = 0.810; 2-sided
t-test, P = 0.379). The difference between the groups for
change in average activity was significant at the 10% level
(P = 0.063, 2-sided t-test), but not at the critical p-value
(0.05) set a priori before the study initiated. Figure 4 illus-
trates the change (final week minus baseline) in mean ac-
tivity per minute over 24 hours. The difference between
the groups for change in activity over the time period
9am-5pm (8 hours) was significant, with the NV-01 group
being more active than the placebo group (P = 0.006).
Joint pain score
There were no changes detected within groups over time
(D-7 to D28) for either total pain score or index joint
pain score. Neither were there any differences between
groups at individual time points (data not shown).
Quality of life (QoL) score
The NV-01 group significantly improved over time (at
D28, P = 0.002). The placebo group did not improve over
time (at D28, P = 0.376). There were no statistical differ-
ences between the groups at any time point for absolute
scores, or change in scores. These scores and changes
are tabulated in Table 7.
Laboratory values
At screening (Day -7), there were a few notable differences
between the groups in hematology parameters, with the
placebo group having higher white blood cell count,
higher hemoglobin, higher hematocrit and lower mean
corpuscular volume. These differences were not statisti-
cally significant. Additionally, red blood cell count values
were significantly higher in the placebo group (P = 0.024).
At D28, there were several significant differences be-
tween the groups in hematology parameters: red blood
cell count values were significantly higher in the placebons for the Canine Brief Pain Inventory Pain Severity
0 minus D14 Within group
change P-value
D0 minus D28 Within group
change P-value
50 (-0.75 – 4.50) 0.012 1.50 (-0.75 – 4.00) 0.019
75 (-2.50 – 4.25) 0.164 0.75 (-2.00 – 4.25) 0.347
226 0.210
provement. Significant P-values are denoted in bold type.
Table 4 Summary of medians, range and statistical comparisons for the Canine Brief Pain Inventory Pain Interference
Scores (CBPI PIS) at D0, D14 and D28 of the study
Group D0 D14 D28 D0 minus D14 Within group
change P-value
D0 minus D28 Within group
change P-value
NV-01 4.50 (1.17 – 9.00) 2.20 (0.20 – 6.30) 3.17 (0.67 – 8.17) 1.63 (-0.63 – 5.37) 0.012 1.92 (-2.50 – 4.34) 0.032




0.939 0.106 0.384 0.0734 0.289
Decreases in scores signify improvement, and positive values for change indicate improvement. Significant P-values are denoted in bold type.
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the placebo group (P = 0.01); hematocrit was signifi-
cantly higher in the placebo group (P = 0.011); packed
cell volume was higher in the placebo group (P = 0.003).
To further evaluate these findings, these values were
examined for significant within group changes. The only
significant change within groups was a significant de-
crease in packed cell volume in the NV-01 group (P =
0.03). No values in any dog were considered clinically
significant, and all values remained within the reference
range. In the NV-01 group, 9/13 had a drop in PCV,
compared to 5/13 in the placebo group. The median
values for each group at each time point are docu-
mented in Table 8.Anti-NV-01 antibody assay in canine plasma
Using a competition binding ELISA format, the presence
of anti-NV-01 neutralising antibody responses was evident
if the concentration of NV-01 measured in the presence of
plasma from NV-01-treated dogs was markedly lower than
the concentration measured in the presence of plasma
from placebo-treated dogs or in the absence of plasma. By
this assay, no neutralizing antibodies (neutralizing anti-
bodies to the anti-NGF antibody) were detected in the
D28 plasma of any dogs tested (n = 12).Discussion
Using a randomized, parallel group, stratified, double
masked, placebo controlled, proof of principle clinical study
design we supported our hypothesis that a single treatment
of NV-01 would decrease pain and improve mobility over a
4-week time period in dogs with DJD-associated pain, asTable 5 Summary of medians, range and statistical compariso
(CSOM) at D0, D14 and D28 of the study
Group D0 D14 D28 D0 m
NV-01 6.0 (4 – 11) 4.0 (0 – 7) 3.5 (0 – 9) 3.0 (-1
Placebo 6.0 (5 – 11) 5.0 (3 – 8) 6.0 (3 – 9) 0.0 (-1
Between group
comparison P-value
0.548 0.011 0.032 0.038
Decreases in scores signify improvement, and positive values for change indicate immeasured by owner-completed clinical metrology instru-
ments (CMIs) and objectively measured activity.
These positive findings pertain to dogs where owners
have noticed activity or mobility impairment, and in which
subsequent diagnostics confirmed the presence of DJD.
We believe our findings are transferable to the general ca-
nine population suffering from DJD-associated pain. DJD
is an umbrella term describing degeneration of synovial
and cartilaginous joints [19]. Many studies describe the in-
clusion of dogs with only OA (or at least do not describe
whether dogs also have other DJD) [20,21], however it is
our experience [22,23] that dogs with appendicular OA
commonly have pain on palpation of regions of the spine,
and radiographic evidence of axial skeleton DJD (degener-
ate intervertebral disks; spinal spondylosis; facet joint
OA). Therefore, in order to test NV-01 in a relevant popu-
lation, we included dogs with appendicular DJD or spinal
DJD, or both. All of the dogs in our study had painful ap-
pendicular DJD, but in 6 of 26 dogs the index area was in
the axial skeleton. All of these dogs had radiographic evi-
dence of facet joint degeneration (OA of the facet joints),
but also evidence of intervertebral disk degeneration or
spinal spondylosis. It is unknown whether the pain elicited
on palpation was a result of facet joint OA or interverte-
bral disk joint DJD. Regardless, we believe this cohort of
dogs reflects the dogs presenting in practice for musculo-
skeletal pain due to DJD, and we believe the term ‘DJD-as-
sociated pain’ more accurately reflects these individuals.
We were careful to exclude dogs with any neurological
deficits. Unlike the majority of participants in the human
clinical studies of anti-NGF mAbs [10-14], we did not tar-
get dogs that had failed other treatments, or where previ-
ous treatments were not appropriately effective.ns for the Client Specific Outcome Measures scores
inus D14 Within group
change P-value
D0 minus D28 Within group
change P-value
– 8) 0.004 3.0 (0 – 6) 0.001
– 3) 0.031 0.0 (-1 – 3) 0.078
0.009
provement. Significant P-values are denoted in bold type.
ab
Figure 2 Change in LOAD scores over time in dogs administered
anti-NGF antibody or placebo. a. Change from baseline in LOAD
(median [solid line], interquartile range [shaded area] and extreme
values [whiskers]) in dogs treated with a single 200 mcg/kg
intravenous injection of anti-NGF antibody on D0. b. Change from
baseline in LOAD (median [solid line], interquartile range [shaded
area] and extreme values [whiskers]) in dogs treated with a single
intravenous injection of placebo (saline) on D0.
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often used as an objective measure of changes in limb
use in relation to joint pain in dogs [20,22-25]. However,
many dogs present with multiple joint OA and only a
small subset of the canine population with OA has obvi-
ous asymmetry in limb use, which is optimal for kineticTable 6 Summary of medians, range and statistical compariso
at D0, D14 and D28 of the study
Group D0 D14 D28 D0 m
NV-01 24.0 (15-44) 16.0 (2-33) 18.0 (5-39) 11.0 (
Placebo 23.0 (13-49) 22.0 (9-40) 23.0 (8-37) 2.0 (-
Between group
comparison P-value
P = 1.00 P = 0.149 P = 0.200 P = 0
Decreases in scores signify improvement, and positive values for change indicate imevaluation [26]. We therefore used global measures that
pertain to pain relief – owner-completed clinical metrol-
ogy instruments and an objective measure of activity –
rather than focus on measures of limb use.
The CMIs we used have all undergone various degrees
of validation (responsiveness, criterion validation), with
the CBPI and the LOAD being the most evaluated and
considered the most valid [26-29]. The CSOM has not
been formally tested for criterion validity, but has shown
responsiveness with known analgesics [30] and a puta-
tive analgesic [1]. In the present study, all the CMI data
led to similar conclusions, with the CSOM and LOAD
appearing most sensitive to changes associated with
treatment. We found significant positive effects of treat-
ment, and this was surprising given the relatively small
numbers of dogs. Recent work [26] found ‘strong’ correl-
ation between the LOAD and the CBPI PSS and PIS.
However, it was clear in that study there was not perfect
correlation, suggesting that the two CMIs are measuring
slightly different aspects and this is supported by our
current data. Currently, it is not known exactly how dif-
ferent CMIs vary in what they are assessing. What is
clear is that despite attempts to validate the CMIs with
objective measures of limb use (ground reaction forces)
or activity (accelerometry measures), only weak correl-
ation is found for ground reaction forces (GRF) or accel-
erometry [26]. One explanation may be that the CMIs
are not optimally designed. However, the fact they show
robust responsiveness to treatment in masked studies,
suggests CMIs, GRFs and accelerometry are measuring
different aspects of outcome. This supports the inclusion
of these different measures of outcome in clinical stud-
ies. An important question that remains unanswered is
‘which of these outcome measures is most relevant to
the dog?’ It is becoming increasingly recognized that the
different outcome measures are assessing different as-
pects of the multifactorial pain experience.
Overall, the degree of reduction in pain over placebo
across the CMIs was approximately 30% (15-40%), which
is considered clinically relevant in human medicine.
When evaluating the effect size of the change in LOAD,
we found a large effect size at both D14 and D28. To-
gether, our data suggest a relatively large effect of NV-
01, but could also represent Type I error. Further studiesns for the Liverpool Osteoarthritis in Dogs Index (LOAD)
inus D14 Within group
change P-value
D0 minus D28 Within group
change P-value
-3-19) P = 0.004 5.5 (-2-18) P = 0.002
6-10) P = 0.099 1.0 (-7-12) P = 0.348
.014 P = 0.033






































Hour of the day
Figure 3 Graph of the mean activity count per minute over each hour of the day for all dogs during the baseline period.
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current findings.
Conversion of CMI data to success/failure has been re-
cently described for the CBPI [31] and the CSOM [30].
We used these recommendations, and found significantly
more treatment successes at D28 using the CSOM. This
was surprising because to detect significant differences
using success/failure analysis requires large differences be-
tween the groups or large numbers of animals, and is not
usually seen with relatively small group sizes. Additionally,
the distribution of success/failure for the CBPI (46%/8%)
and CSOM (67%/23%) was very similar to previous studies
using the NSAIDs carprofen (CBPI evaluation - 46% suc-
cess in carprofen group, 23% success in the placebo group
[31]) and meloxicam (CSOM evaluation - 73% success in
meloxicam group, 47%% success in the placebo group
[30]) The present CMI data suggests the efficacy of a sin-
gle dose of NV-01 is at least identical to that of daily
NSAID administration. Currently, the duration of action is
unknown, and further work is needed to determine this.
Treatment-related effects on activity as measured by
accelerometry were seen, particularly for the day-time
period. The accelerometers we used have been shown to be









































Figure 4 Graph of mean change (week 4 minus baseline) in activity count
and the placebo group (solid line).successfully detected changes in activity related to NSAID
administration in clinical studies in dogs [33]. Activity is
highly variable from day to day both within and between
dogs [34]. Given this variability, we elected to assess a
change in activity over time within individual dogs, using 7-
day blocks of time [34]. We detected improved day-time
activity in the NV-01 group over the placebo group. Look-
ing at the 24-hour profile of activity at baseline, it might
have been expected to see changes in the peaks of activity.
However, the peaks of activity (morning and evening) are
likely defined by owner activity and owner interaction with
the dogs. Conversely, the activity during the daytime (when
owners are at work) may be more representative of spon-
taneous activity. Little work has been performed on how
analgesic therapy changes the profile of activity over the
day, and further work, including capturing owner sched-
ules, is required to better understand this.
The dose used was based on earlier work with NV-01
that suggested 200 mcg/kg showed analgesic efficacy in
the kaolin model of inflammation [16]. Our current data
appears to confirm the efficacy of NV-01 and indicates
that efficacy lasts for at least 28 days following a single in-
jection. No neutralizing antibodies were detected in any of
the dogs treated with NV-01, that is, no antibodies to the12 13 14 15 16 17 18 19 20 21 22 23 24
of the day
per minute for each hour of the day in the NV-01 group (dotted line)
Table 7 Summary of medians, range and statistical comparisons for the Quality of Life index (QoL) at D0 and D28 of
the study
Group D-7 D28 D28 minus D-7) Within group change P-value
NV-01 1730 (20-5940) 500 (0-5520) 677 (-110-2850) P = 0.002
Placebo 2040 (580-9100) 1880 (350-7210) 200 (-1305-4450) P = 0.376
Between group comparison P-value P = 0.184 P = 0.060 P = 0.221
Decreases in scores signify improvement. Significant P-values are denoted in bold type.
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the pharmacokinetic profile of NV-01 and the duration of
efficacy from a single dose. In the human clinical trials,
several versions of anti-NGF mAbs have been evaluated,
and overall, efficacy is detected within 2 weeks and ap-
pears to last at least 8 weeks [10-15]. The majority of pa-
tients enrolled into these human clinical trials are patients
in which pain was not adequately controlled by NSAIDs
and/or opioids, which is in contrast to our canine study
inclusion criteria. Of interest, all the basic studies on anti-
NGF were performed in rodent models of inflammatory
arthritis or inflammatory pain. No studies have been per-
formed in rodent models of OA or non-inflammatory
DJD, making this current study the first placebo-
controlled evaluation of anti-NGF in a non-human model
of non-inflammatory DJD. If further work confirms the ef-
ficacy of NV-01 in dogs with DJD-associated pain, it will
be a demonstration of the predictive validity of the ‘spon-
taneously –occurring canine DJD model’ (that is, DJD in
owned companion pet dogs) for human conditions.
The present study was not appropriately powered to
assess the potential for side effects. In human clinical tri-
als, two main types of side effects have been seen with
anti-NGF mAbs – neurological effects and effects on the
progression of OA [15]. We performed a neurological
evaluation of all dogs at 28 days following treatment and
did not detect any neurological abnormalities. Many of
the neurological side effects in people were peripheral
sensory symptoms, primarily paresthesia, hypoesthesia
and hyperesthesia. It is unlikely these would be detected
in canine patients by a detailed clinical neurological
evaluation such as we performed. Future work should
use quantitative sensory testing (QST) methods that are
being developed in dogs [35-37] to more completelyTable 8 Summary of the median (min, max) values for each tr
for selected hematology parameters
NV-01 D-7 NV-01 D2
WBC (x103/UL) 8.47 (5.34,11.62) 9.27 (5.41
RBC (x106/UL) 6.39 (5.38,7.39) 6.06 (5.14
HGB (G/DL) 15 (13.1,18.7) 14.65 (11.
HCT (%) 44.4 (36.8,55.1) 42.3 (34.8
PCV (%) 45 (37,53) 41.5 (35,4
WBC =White blood cell count; RBC = red blood cell count; HGB = hemoglobin; HCTevaluate sensory function changes. Human clinical stud-
ies of anti-NGF mAbs were halted by the FDA due to a
signal of adverse events related to rapidly progressing
osteoarthritis (RPOA) in approximately 1% of treated pa-
tients. This occurred in diseased joints, but there were
also some cases that occurred in previously asymptom-
atic joints [15]. The mechanism of this RPOA is not
understood. We saw no cases of worsening joint pain in
our study, but a significantly larger cohort of treated dogs
would be needed to detect whether or not a similar side
effect is seen in dogs. There is no data in veterinary medi-
cine on the normal rate of progression of OA in dogs, and
this should be an area targeted with clinical research prior
to the advent of anti-NGF mAbs in veterinary medicine.
In the present study, we did detect a statistically signifi-
cant, but clinically benign, change in packed cell volume
in the NV-01 treated group. The reason for this is un-
known, and it has not been reported in human studies.
This should be evaluated carefully in subsequent studies.
Conclusions
This pilot, masked, placebo-controlled clinical study suggests
efficacy of NV-01, a monoclonal canine-specific antibody
against nerve growth factor, in reducing spontaneous DJD-
associated pain and improving mobility in dogs. Owner-
assessed indices of pain and mobility were significantly
improved in NV-01 treated dogs compared to placebo, and
objectively measured activity increased significantly more
in the NV-01 treated dogs during the daytime period.
Methods
Design
This was a randomized, stratified, double masked, pla-
cebo controlled, proof of principle clinical pilot studyeatment group at screening (D-7) and end of study (D28)
8 Placebo D-7 Placebo D28
,13.22) 9.57 (5.85,14.48) 9.91 (5.72,14.47)
,7.25) 6.99 (5.95,8.1) 6.78 (5.69,8.27)
9,16.7) 16.4 (14.2,18.1) 16.3 (14,19)
,47.4) 47.2 (42.2,52.2) 47.3 (39.4,53.8)
8) 47 (43,53) 47 (40,53)
= hematocrit; PCV = packed cell volume.
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Care and Use Committee (IACUC) approved this study
(IACUC #12-149-O), and in all cases owners signed a
written consent form following a detailed verbal explan-
ation of the study protocol.
Study population
Dogs ≥1-year old and ≥15 kg with DJD-associated pain
and mobility impairment were recruited. Recruitment was
performed using advertisements on the NCSU-CVM in-
ternal TV monitors, through NCSU websites, e-mail ad-
vertisement to NC State university colleges (Education,
Engineering), via direct advertising to local veterinarians
and newspaper advertisements run in local weekly news-
papers. Promotion of the study was also done using the
NCSU-CVM social media sites (NCSU-CVM blog, Twit-
ter feed and Facebook page). Recruitment began mid-
April 2013 and continued through mid-October 2013.
Inclusion criteria
To be eligible for the study, dogs were required to have
impaired mobility of a certain severity, as judged by
owners, no detectable systemic disease, and at least one
appendicular joint or axial skeleton area that was consid-
ered painful and where radiographs showed the presence
of DJD (see ‘Study Protocol’). Radiological features used
to establish the presence of DJD in appendicular joints
were: joint effusion, osteophytes, sclerosis, subluxation,
subchondral bone erosions and cysts and presence of
intra-articular mineralization. Radiological features used
to establish the presence of DJD in the axial skeleton
were: osteophytes, spondylosis, disc-associated degener-
ation (end plate sclerosis, erosion, disc mineralization, nar-
rowing) and subluxation. Additionally, dogs were required
to not be currently receiving any anti-inflammatory medi-
cations (NSAIDs) or other analgesics (e.g. amantadine,
gabapentin, tramadol). Other analgesics (e.g. amantadine,
gabapentin, tramadol) were permitted if it was deemed
there was currently significant pain associated with the
DJD, and the dog had been on the medication(s) for at
least 3 weeks. Dogs were required to be either not receiv-
ing nutritional supplements, or have been on them for 6
weeks or more before the start of the study. A two week
withdrawal period was required prior to study entry for
dogs discontinuing nutritional supplements, NSAIDs or
other analgesics. If dogs were considered to be mobility
impaired but no DJD was detected radiographically, or if
they had DJD but the impairment in mobility was not suf-
ficient, they were not enrolled. Other exclusion criteria in-
cluded known or suspected presence of any of the
following conditions: clinically significant cardiovascular
disease; severe dental disease; neurological disease, renal
disease; liver disease (ALT levels of up to twice the upper
normal value and AlkPhos levels of up to four times theupper normal value were considered acceptable in the ab-
sence of other signs of liver disease); chronic pulmonary
disease; infectious disease; immune-mediated disease; neo-
plasia; urinary tract infection; hypothyroidism (unless well
controlled); diabetes mellitus; skin disease of the foot;
obesity (8 or 9 out of the 1-9 Body Condition Score Scale).
These were exclusion criteria because they may be associ-
ated with decreased activity that would not respond to an-
algesic treatment. Particular attention was given to ruling
out neurological disease through a comprehensive neuro-
logical evaluation. Additionally, owners had to agree to
not change the management of dogs for the period of the
study, and owners were required to have a stable lifestyle
for the duration of the study (no planned house moves,
vacations, relationship changes or new pets).
Study protocol
The study was conducted over a 28-day period with out-
come measures gathered at screening (D -7) and on D0,
D14 and D28.
Approximately 7 days prior to starting on the study,
potential candidate dogs were screened using a general
physical, neurological and orthopedic examination,
complete blood count, serum biochemistry and urinaly-
sis. Physical and orthopedic examinations were per-
formed by the same examiner (MF) throughout the
study. Pain on manipulation of each appendicular joint
and manipulation of each region of the axial skeleton
was assessed and recorded using a 5-point scale (Additional
file 1). Scores were summed across all appendicular
joints (manus, carpus, elbow, shoulder, pes, hock, stifle,
hip) and each region of the axial skeleton (cervical, thor-
acic, thoraco-lumbar, lumbar, lumbo-sacral) to create a
total pain score (maximum score 84). In addition, an
index joint or region of the axial skeleton was defined,
and the index joint/region pain score recorded. The
index joint/region was defined based on clinical judg-
ment of what was the most severely affected area, with
the predominant criterion being the pain score for that
area. Based on the orthopedic examination (pain and
function), dogs were designated as being either pre-
dominantly ‘Fore’ (forelimb, neck or thoracic spine) or
‘Hind’ (hind limb, thoraco-lumbar, lumbar or lumbo-
sacral spine) impaired. Digital radiographs of all clinic-
ally abnormal (painful) appendicular joints or areas of
the axial skeleton were taken under sedation. Owners
completed three clinical metrology instruments (CMIs) -
the Client Specific Outcome Measures (CSOM) [1,30] the
Canine Brief Pain Inventory (CBPI) [27,28] and the Liver-
pool Osteoarthritis in Dogs Index (LOAD) [26,29]. Owners
also completed a Quality of Life Index (Additional file 2),
constructed in a similar manner to previous reports [38,39].
Dogs were required to have a qualifying degree of mobility
impairment as reported and scored by the owner on the
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scored on a 0-4 scale where 0 = normal, 4 = impossible
to perform the activity). Dogs were fitted with a collar-
mounted accelerometer (see below). Owners were asked
to keep a diary of any unusual events that might affect a
dog’s activity.
On D0, owners returned to the clinic with their dogs,
and completed the CMIs again. The physical, orthopedic
and neurological examinations were repeated to ensure
there were no changes and no additional findings. On
D0, dogs were administered the anti-nerve growth factor
antibody (NV-01) or placebo, at a dose of 200 mcg/kg of
a 2 mg/ml solution administered IV over a 1-minute
period through an intra-venous 20G catheter. Normal
saline was used as the placebo, and administered IV at a
volume equivalent to the dose of NV-01. Following test
article administration, dogs were observed for a period
of 4 hours for any signs of an allergic reaction.
On D14, owners returned to the clinic and completed
the CMIs and the physical, orthopedic and neurological
examinations were repeated to ensure there were no
changes or additional findings.
On D28, owners returned to the clinic and completed
the CMIs, the physical, orthopedic and neurological ex-
aminations were repeated and joint pain scored. The
data from the accelerometer was downloaded, and sam-
ples collected for CBC, clinical chemistry and urinalysis.Randomization to treatment groups
Dogs were randomized to receive the drug or placebo
on D0 based on a stratified, blocked design. Stratification
was based on predominant site of problem (Fore or
Hind), and total CBPI score (<50, ≥ 50). Hence, the
stratification groups were: CBPI < 50/Fore; CBPI < 50/
Hind; CBPI ≥ 50/Fore; CBPI ≥ 50/Hind.
Within each stratification, randomization of treatment
occurred in groups of 2 (e.g. placebo, then NV-01; or,
NV-01 then placebo). The randomization schedule and
the key were held by the NCSU pharmacy and not dis-
closed to investigators. The dispensing of drug/placebo
was performed by NCSU pharmacy, with all other
personnel involved in the evaluation of dogs and collec-
tion of data masked to the administration until comple-
tion of the statistical analysis. Pharmacy staff prepared
unmarked syringes for each patient with the barrel cov-
ered in opaque tape. Testing prior to starting the study
indicated there was no appreciable difference between
the feel of injecting saline versus NV-01 through a 20G
catheter, allowing masking to be complete.Outcome measures
The primary outcome measures were the CMIs and acti-
metry data. Secondary outcome measures were indexjoint pain, total joint pain score, owner-assessed side ef-
fects, hematology, clinical chemistry and urinalysis.
Clinical metrology instruments
CMIs were completed by the same owner at all visits,
and owners were directed to base their answers on their
observations of the preceding seven days. The owners
completed the CMIs while sitting or standing (as they
preferred), in a standard consulting room. At each time
point, they were requested to complete the CMIs and
the instructions were explained to them in a neutral
tone of voice. Owners completed the CMIs while their
dog was being examined in a separate room.
The LOAD [26,29] is a 13-item instrument with all
items reported on a five-point Likert-type scale. Each item
is scored 0 to 4, and the item scores are summed to give
an overall instrument score. The CBPI [27,28] is a two-
part instrument. The pain severity score (CBPI PSS) is the
arithmetic mean of four items scored on an 11-point (0 to
10) numerical scale, and the pain interference score (CBPI
PIS) is the mean of six items similarly scored. The CSOM
[30] is a CMI that follows 3 activities unique to the indi-
vidual dog that are determined to be impaired. It is mod-
eled after the Cincinnati Orthopedic Disability Index,
CODI [40]. The CSOM was constructed by a single study
individual (BC) for each case as previously described [1]
but only defining 3 activities as more recently described
[30]. At each time point, the difficulty performing each of
the 3 activities was scored on a 0-4 scale: 0 = No Problem,
1 =Mildly Problematic, 2 =Moderately Problematic, 3 =
Severely Problematic, and 4 = Impossible. The CSOM
score resulted from the addition of the score for each ac-
tivity. Only complete CMIs were considered valid.
Activity monitoring (AM)
As previously reported [23,26,33], the spontaneous activ-
ity of each individual dog was measured using an accel-
erometera, a method termed actimetry. Actimetry
commenced following screening and continued for the
duration of the study. At D28 the monitor was removed
from the collar and placed on a telemetric reader to
download the data to a personal computer.
Statistical analysis
This was a pilot study, and the potential degree of im-
provement associated with anti-NGF antibody was not
known, and so the number of dogs was based on the fol-
lowing. From a previous study carried out at our site [23],
change in mean pain interference CBPI score following 2-
weeks of an NSAID was 1.4 (baseline = 2.9; after NSAID
for 14d = 1.5) and the mean standard deviation was 1.2.
Using this standard deviation, and data from a study [28]
where the improvement in CBPI interference score was 0.2
for placebo, and 1.1 for NSAID, we determined that a total
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which was considered acceptable for a pilot study.
All data were entered into hard-copy notebooks, and
then transcribed to digital files. All data underwent
100% quality control by two individuals not associated
with the study to verify the digital entries. Descriptive
statistics were used to describe the demographic charac-
teristics of the two groups, and appropriate statistical
tests used to compare these characteristics.
For all subjective parameters (CMIs, joint pain, QoL),
the change within groups over time, and the difference
in change between groups were assessed statistically.
Data were compared non-parametrically. Data were con-
verted to success/failure where published guidelines
were available, and analyzed using a Fisher’s Exact test.
For the CBPI data, success/failure at D14 and D28 was
defined based on an improvement of at least 1 for CBPI
PSS, and at least 2 for CBPI PIS, with inclusion criteria set
as a CBPI PSS and CBPI PIS of at least 2 at baseline (D0).
For the CSOM, success/failure at D14 and D28 was de-
fined as an improvement of 2 or more on the total CSOM,
with no deterioration in any single CSOM activity.
Actimetry data were extracted for days -7 to -1 (base-
line), and 20 to 27 (final week of study). For each dog, the
average activity count per minute over each 7-day period
was calculated and used for analysis. Activity data were
normally distributed, and within-group changes evaluated
using a paired t-test. Between group comparisons were
not performed due to the large inter-dog variations in
baseline activity, and recent data from our group indicat-
ing significant differences in output between accelerome-
ters (unpublished data). In addition, the within-group
change in mean activity per minute for each hour of the
day was compared for several segments of the day.
Laboratory data were compared between groups at the
start and end of the study (Wilcoxon Rank Sums).
Where significant differences between groups were de-
tected, they were further examined for within group
changes (Wilcoxon Signed Rank).
In all analyses, the critical P-value was set as 0.05. Due
to the pilot nature of the study, the P-value was not ad-
justed for multiple comparisons within any outcome
measure, and additionally, in some results, both the one-
sided and two-sided statistical test results are described.
ELISA assay for neutralizing antibodies to NV-01
Plasma samples were assayed in a competition ELISA for
inhibition of binding of purified NV-01 to mouse NGF.
Purified NV-01 was mixed with dog plasma from placebo-
or NV-01-treated dogs and added to plates previously
coated with mouse NGF. Following incubation, blocking
and washing, binding was detected using secondary anti-
canine IgG polyclonal antibody-HRP conjugate [16]. Puri-
fied NV-01 without dog plasma, in the absence or presenceof a neutralizing anti-NV-01 mouse monoclonal antibody
(1RC1) was used as negative and positive controls.
Endnote
aActical Activity Monitor, Philips Respironics Co,
Bend, OR.
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Additional file 2: Global weighted quality of life score (canine).
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